氧化对风湿性关节炎患者长期恶性瘤风险具有中性作用:基于人口的回顾性队列研究
Xiu-Juan Hou1, Renin Chang2,3, Yu-Hsun Wang4
1Department of Rheumatism, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
International journal of rheumatic diseases
|March 7, 2024
概括
氧化 (HCQ) 的使用不会增加类风湿性关节炎 (RA) 患者的癌症风险. 这项研究发现,在RA患者中,HCQ和随后的恶性瘤之间没有显著的关联.
科学领域:
- 类风湿病学 类风湿病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 风湿性关节炎 (RA) 患者面临着讨论过的癌症风险.
- 氧化 (HCQ) 可能会提供预防癌症的保护.
- 研究HCQ在RA恶性瘤风险中的作用至关重要.
研究的目的:
- 确定HCQ使用与RA患者随后的癌症风险之间的关联.
- 评估HCQ在RA中的潜在化学预防作用.
主要方法:
- 从国家医疗保险研究数据库中确定了RA患者.
- 倾向性得分匹配 (1:1) 用于创建可比的HCQ用户和对照组.
- 卡普兰-梅尔曲线和考克斯比例危险模型分析了癌症风险.
主要成果:
- 分析了492名符合条件的RA患者 (每组246人).
- 使用HCQ显示出中性癌症风险 (调整后危险比,0.99;95% CI,0.44-2.21).
- 没有发现违反比例危险假设的情况.
结论:
- 作为一种主要的RA治疗方法,HCQ似乎无法预防癌症.
- 在RA患者中,HCQ与恶性瘤的风险增加无关.
- 对HCQ的机制进行进一步研究是有必要的.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Hazard Ratio
121
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
121
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K


